Bio*One Capital is the dedicated biomedical sciences investment arm of the Singapore Economic Development Board (“EDB”). We manage S$1.2 billion (approximately US$790 million) in funds that invest in global biotechnology, specialty pharmaceuticals, medical technology companies and start-ups in Singapore. In addition to generating long-term capital gains, we seek to accelerate the growth of a vibrant biomedical sciences industry in Singapore through scientific and economic contributions from our investment activities. Bio*One Capital currently has a portfolio of over 60 companies worldwide.

Bio*One Capital has a long history of investing in high-growth and impactful biomedical sciences ventures and made our first biotech investments in 1990. We are today a leading investment management company for biomedical sciences in Asia with a global presence through EDB offices in US, Europe and Japan.

Bio*One Capital invests in promising companies where we can play a value adding role in supporting their growth strategies through operations in Singapore. To achieve this, Bio*One Capital offers a strong combination of financial, business, scientific and investment know-how to enhance the value of companies, from intellectual property generating research, to clinical and product development, manufacturing and commercial activities.

We work actively with management teams and entrepreneurs towards the common goal of creating value and sustainable businesses. Through our extensive networks with global biomedical companies and venture capital corporations, we proactively facilitate partnering and collaborative opportunities. In addition, we work closely with EDB's Biomedical Sciences Group and Agency for Science, Technology and Research’s (A*STAR), Biomedical Research Council to help our portfolio companies nurture their business operations in Singapore.